ArticlePLoS computational biology2025
Predicting Affinity Through Homology (PATH): Interpretable binding affinity prediction with persistent homology.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Topological deep learning for drug-target interaction, virtual screening, and docking scoring: a practical, benchmark-driven review.Briefings in bioinformatics · 2026Review
- A Review of Topological Data Analysis and Topological Deep Learning in Molecular Sciences.Journal of chemical information and modeling · 2025Review
Corrections and comments
- Update of
Authors and funding
2 authors.
Funding
Abstract
Accurate binding affinity prediction (BAP) is crucial to structure-based drug design. We present PATH+, a novel, generalizable machine learning algorithm for BAP that exploits recent advances in computational topology. Compared to current binding affinity prediction algorithms, PATH+ shows similar or better accuracy and is more generalizable across orthogonal datasets. PATH+ is not only one of the most accurate algorithms for BAP, it is also the first algorithm that is inherently interpretable. Interpretability is a key factor of trust for an algorithm and alongside generalizability, which allows PATH+ to be trusted in critical applications, such as inhibitor design. We visualized the features captured by PATH+ for two clinically relevant protein-ligand complexes and find that PATH+ captures binding-relevant structural mutations that are corroborated by biochemical data. Our work also sheds light on the features captured by current computational topology BAP algorithms that contributed to their high performance, which have been poorly understood. PATH+ also offers an improvement of 𝒪 (m + n)3 in computational complexity and is empirically over 10 times faster than the dominant (uninterpretable) computational topology algorithm for BAP. Based on insights from PATH+, we built PATH-, a scoring function for differentiating between binders and non-binders that has outstanding accuracy against 11 current algorithms for BAP. In summary, we report progress in a novel combination of interpretability, speed, and accuracy that should further empower topological screening of large virtual inhibitor libraries to protein targets, and allow binding affinity predictions to be understood and trusted. The source code for PATH+ and PATH- is released open-source as part of the OSPREY protein design software package.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.